TABLE 2.

PharmGKB drug label annotations.

Gene	Drug class	Relationship	Drug	FDA/EMA label	Evidence score/Summary
BRCA1/2	PARP-inhibitors	Sensitivity	Niraparib	FDA: ZEJULA	Testing required
			Olaparib	EMA: LYNPARZA	Testing required
				FDA: LYNPARZA
			Rucaparib	EMA: RUBRACA	Testing required
				FDA: RUBRACA
			Talazoparib	EMA: TALZENNA	Testing required
				FDA: TALZENNA
RET	Tyrosine Kinase Inhibitors	Sensitivity	Vandetanib	EMA: CAPRELSA	Testing recommended
			Pralsetinib	FDA: GAVRETO	Testing required
			Selpercatinib	FDA: RETEVMO	Testing required
			Cabozantinib	FDA: COMETRIQ	Informative PGx
TP53	BCL-2 Inhibitors	Sensitivity	Venetoclax	FDA: VENCLEXTA	Informative PGx

Description of current drug label annotations for genes investigated in this study, including links to drug label. Results were obtained from PharmGKB.